Community curated by people like you

Johnson & Johnson stories

Oct 20, 2026

Rapport Therapeutics' RAP-219 meets primary endpoint in phase 2 bipolar mania trial

Rapport Therapeutics announced positive phase 2 results for RAP-219, an oral AMPA receptor modulator licensed from Johnson & Johnson, showing improvement in bipolar mania symptoms. This marks the company's second phase 2 success for the asset in 14 months.

Oct 20, 2026·3 sources

00

Top claims

▪RAP-219 is an oral candidate licensed from Johnson & Johnson that functions as a TARPγ8-selective AMPA receptor negative allosteric modulator.
▪Rapport Therapeutics expects to initiate Phase 3 trials for RAP-219 in acute bipolar mania in the second half of 2027.
▪William Blair analysts stated that the trial results validate RAP-219's proof-of-concept beyond epilepsy, supporting its multi-blockbuster potential across multiple indications.

Topics

Drug development Bipolar disorder Neuroscience Mental health Clinical trials